Clinical trials · New York, NY
Prostate cancer clinical trials in New York
We’re tracking 165 recruiting prostate cancer studies with a site in or near New York — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near New York
- NCT07285057RecruitingPhase 2
New PET scan for men with low-risk prostate cancer on active surveillance
This trial tests a new imaging test called rhPSMA-7.3 (18F) PET/CT to see if it can better detect prostate cancer in men who are on active surveillance because their cancer is considered low-risk or favorable intermediate-risk. You would also get an MRI and a biopsy as part of the study.
New York, New YorkAges 18 years+ - NCT04787744RecruitingPhase 2/Phase 3
Test standard prostate cancer treatment with or without targeted spot radiation
This study tests whether adding targeted local treatment (like radiation to a few spots seen on scans) improves outcomes for some people with limited (oligometastatic) prostate cancer. It compares standard systemic therapy alone versus standard therapy plus PET-scan–guided spot treatment.
New York, New YorkAges 18 years+ - NCT06825715Recruiting
Precision oncology support for lung and prostate cancer
This study tests a program to help veterans with lung or prostate cancer get personalized cancer treatments. The goal is to see if extra support for doctors and patients leads to better use of precision medicine.
New York, New YorkAges Any age - NCT06067841RecruitingPhase 1
New drug for advanced prostate cancer
This study tests a new drug (BMS-986460) for people with advanced prostate cancer that has stopped responding to hormone therapy. It aims to see if the drug can shrink or slow the cancer.
New York, New YorkAges 18 years+ - NCT07611110RecruitingPhase 3
AZD2265 vs standard care for advanced prostate cancer
This trial tests a new cancer-fighting drug called AZD2265 against standard treatment for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. You may qualify if your cancer previously responded to PSMA-targeted radiation treatments but is now growing again.
New York, New YorkAges 18 years+ - NCT06844383RecruitingPhase 2
Talazoparib with or without enzalutamide for prostate cancer after prior treatment
This study tests a drug called talazoparib, either alone or combined with enzalutamide, in people with prostate cancer that has spread and has a specific genetic change. The goal is to see if this treatment can help control the cancer after previous therapies have stopped working.
New York, New YorkAges 18 years+ - NCT02706561Recruiting
Helping men stick with erectile rehab after prostate surgery
This study tests a program to help men follow sexual (erection) rehabilitation after prostate cancer surgery. It may help improve or maintain erectile functioning by supporting the right rehab steps in the months after surgery.
New York, New YorkAges 21 years+ - NCT06778863RecruitingPhase 1
A study of CLSP-1025 for adults with certain solid tumors
This trial tests a new drug called CLSP-1025 for people with advanced solid tumors that have a specific change in the p53 gene (R175H). The drug targets this change to help fight the cancer.
New York, New YorkAges 18 years+ - NCT04706663Recruiting
Genomics-guided treatment for people with prostate cancer
This trial uses genetic test results from your prostate cancer to guide treatment choices. It may help find therapies that better match the specific gene changes in your cancer.
New York, New YorkAges 18–120 - NCT05915442RecruitingPhase 2
Adenosine blocker plus immunotherapy for limited prostate spread
This Phase 2 study tests a medicine that affects “adenosine” signaling along with an immune checkpoint inhibitor (immunotherapy) in men with hormone-sensitive prostate cancer that has spread in only a small, limited way. It aims to stop or slow that limited spread by helping the immune system work better.
New York, New YorkAges 18–99 - NCT06855277RecruitingPhase 3
AAA817 with hormone therapy for advanced prostate cancer
This trial tests a new combination treatment (AAA817 plus a hormone therapy) against standard care for men with advanced PSMA-positive prostate cancer that has spread and stopped responding to a previous hormone therapy. It may be an option if you haven't had certain prior treatments.
New York, New YorkAges 18–100 - NCT06172478RecruitingPhase 2
HER3-DXd for advanced solid tumors after prior treatment
This trial tests a new targeted drug called HER3-DXd for people with several types of advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver chemotherapy directly to cancer cells that have a protein called HER3 on their surface.
New York, New YorkAges 18 years+ - NCT07590934RecruitingPhase 1/Phase 2
Drug combination study for advanced prostate cancer
This study tests several new drug combinations for men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. It aims to find better ways to control the disease and improve outcomes.
New York, New YorkAges 18–99 - NCT07052214RecruitingPhase 3
PSMA PET plus MRI to find prostate cancer
This trial tests if combining a PSMA PET scan with an MRI can better detect clinically significant prostate cancer than MRI alone. It may help men who have not had a prostate biopsy before and have certain risk factors.
New York, New YorkAges 18 years+ - NCT03492424Recruiting
Focal prostate cancer treatment study
This study looks at outcomes after “focal therapy,” a type of treatment that targets only part of the prostate, for people with newly diagnosed or returning prostate cancer. It may help researchers understand how well this targeted approach works and for whom.
New York, New YorkAges 18 years+ - NCT04104776RecruitingPhase 1/Phase 2
Test drug tulmimetostat for advanced cancers and lymphomas
This early-phase study tests tulmimetostat (DZR123) to shrink or control advanced solid tumors and certain lymphomas, and it may also test a combination in some prostate cancer groups. If you qualify, you’ll receive the study drug and be monitored closely, including blood tests and a request for tumor tissue to look for biomarkers.
New York, New YorkAges 18 years+ - NCT04986423RecruitingPhase 2
Add ZEN003694 to enzalutamide for resistant prostate cancer
This Phase 2 study tests whether adding ZEN003694 to enzalutamide works better than enzalutamide alone in men whose prostate cancer has spread and is no longer controlled by hormone lowering treatments. It focuses on people who either did not respond well to abiraterone (poor responders) or did respond (responders), then compares outcomes between treatment groups.
New York, New YorkAges 18 years+ - NCT05946213RecruitingPhase 3
Shorter radiation treatment for high-risk prostate cancer
This trial tests whether a shorter course of radiation works as well as the usual longer course for people with high-risk prostate cancer. The goal is to keep cancer control while possibly reducing treatment time and inconvenience.
New York, New YorkAges 18 years+ - NCT04167969RecruitingPhase 1
Nanoparticles to help guide prostate cancer surgery
This Phase 1 study tests nanoparticles (tiny particles) that are meant to help surgeons better find and remove prostate cancer tissue during surgery. You may be offered standard prostate surgery plus imaging with a study tracer to guide the operation.
New York, New YorkAges 18 years+ - NCT06879041RecruitingPhase 1
Study of a radiation drug for advanced prostate cancer
This trial tests a new drug that delivers radiation directly to cancer cells. It is for men with metastatic castration-resistant prostate cancer that has progressed after other treatments.
New York, New YorkAges 18 years+ - NCT07203482Recruiting
HIFU ablation treatment for prostate cancer outcomes
This study collects data on men with early, low-risk prostate cancer who choose to have a targeted ultrasound treatment called HIFU (High-Intensity Focused Ultrasound). It looks at how well this treatment works and how men recover.
New York, New YorkAges 40–95 - NCT04886986RecruitingPhase 1
Testing a targeted radiation pill for advanced prostate cancer
This Phase 1 trial tests a small-molecule treatment that carries radioactive material to help treat prostate cancer that has spread and keeps growing despite standard hormone-blocking treatment. It’s mainly looking to find a safe dose and see how well the approach works in people with limited treatment options.
New York, New YorkAges 18–99 - NCT06807359RecruitingPhase 1/Phase 2
Light-activated therapy for localized prostate cancer
This trial uses a special light-activated drug (photodynamic therapy) to treat prostate cancer that is still confined to the prostate. It aims to destroy the cancer while sparing healthy tissue, and may be an option for people with intermediate-risk prostate cancer who have not had other treatments.
New York, New YorkAges 18 years+ - NCT07871435RecruitingPhase 1/Phase 2
Investigational combo for advanced prostate cancer
This trial tests two investigational drugs together for men with a type of advanced prostate cancer that has stopped responding to standard hormone therapy. The goal is to see if the combination can shrink tumors or slow the cancer's growth.
New York, New YorkAges 18 years+
Hear when a new Prostate cancer trial opens near New York, NY
We’ll email you when one opens near New York, NY — at most once a week, no account needed, unsubscribe anytime.
Prostate cancer trials in other cities
Where these studies are running near New York
Institutions with a site for the recruiting prostate cancer studies listed above.
- Memorial Sloan Kettering Cancer Center · 8 studies
- Research Site · 3 studies
- Weill Cornell Medicine · 3 studies
- Hackensack University Medical Center · 2 studies
- NYU Langone Health · 2 studies
- VA NY Harbor Healthcare System, New York, NY · 2 studies
- Astera Cancer Center
- Brooklyn Methodist Hospital - New York Presbyterian
What taking part in a prostate cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting prostate cancer studies in New York.
Common questions
- Are there prostate cancer clinical trials near New York?
- Yes. We're currently tracking 165 recruiting prostate cancer studies with a site near New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a prostate cancer study near New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site near New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a prostate cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New prostate cancer studies open near New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.